[
  {
    "ts": null,
    "headline": "AstraZeneca: Mispriced Growth Following The Oncology Segment Success",
    "summary": "AstraZeneca aims for $80bn revenue by 2030, highlighting oncology advances and growth potential. See AZN stock's valuation insights and GARP investment case.",
    "url": "https://finnhub.io/api/news?id=d922078a6d39841502ab0a542f64330bcda597a46b2e95905ae31285a31da98e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766111433,
      "headline": "AstraZeneca: Mispriced Growth Following The Oncology Segment Success",
      "id": 137828830,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160089493/image_2160089493.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AstraZeneca aims for $80bn revenue by 2030, highlighting oncology advances and growth potential. See AZN stock's valuation insights and GARP investment case.",
      "url": "https://finnhub.io/api/news?id=d922078a6d39841502ab0a542f64330bcda597a46b2e95905ae31285a31da98e"
    }
  }
]